WE CLAIM:

1. A pharmaceutical composition comprising

   tirzepatide, or a pharmaceutically acceptable salt thereof;

   an agent selected from the group consisting of NaCl and propylene glycol; and

   dibasic sodium phosphate.

2. The pharmaceutical composition as claimed by Claim 1, wherein

   the tirzepatide, or a pharmaceutically acceptable salt thereof,

   concentration is from 5 to 30 mg/mL.

3. The pharmaceutical composition as claimed by Claim 2

   wherein the dibasic sodium phosphate concentration is from 1.0 mg/mL to 3.0 mg/mL.

4. The pharmaceutical composition as claimed by Claim 2 wherein

   the dibasic sodium phosphate concentration is from 0.67 mg/mL to 2.68 mg/mL.

5. The pharmaceutical composition as claimed by Claim 4 wherein the

   dibasic sodium phosphate concentration is 1.34 mg/mL.

6. The pharmaceutical composition as claimed by Claim 1 wherein the

   tirzepatide, or a pharmaceutically acceptable salt thereof,

   concentration is selected from the group consisting of 5, 10, 15, 20, 25, and

   30 mg/mL.

7. The pharmaceutical composition as claimed by Claim 6 wherein the

   tirzepatide, or pharmaceutically acceptable salt thereof, concentration is selected from the group consisting of 10, 20, and 30 mg/mL.

8. The pharmaceutical composition as claimed by Claim 7

   wherein the agent is NaCl.

9. The pharmaceutical composition as claimed by Claim 8 wherein

   the concentration of NaCl is from 6.2 mg/mL to 9.5 mg/mL.

10. The pharmaceutical composition as claimed by Claim 9 wherein the concentration of NaCl is from 7.0 mg/mL to 9.0 mg/mL.
11. The pharmaceutical composition as claimed by Claim 10 wherein the NaCl concentration is 8.2 mg/mL.
12. The pharmaceutical composition as claimed by Claim 1 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from 5 mg/mL to 30 mg/mL; dibasic sodium phosphate concentration is from 0.67 mg/mL to 2.68 mg/mL; and NaCl concentration is from 6.2 mg/mL to 9.5 mg/mL.
13. The pharmaceutical composition as claimed by Claim 12 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from 5 mg/mL to 30 mg/mL; dibasic sodium phosphate concentration is 1.34 mg/mL; and NaCl concentration is 8.2 mg/mL.
14. The pharmaceutical composition as claimed by Claim 13 wherein the composition is presented in an automatic injection apparatus.
15. The pharmaceutical composition as claimed by Claim 1 wherein the agent is propylene glycol.
16. The pharmaceutical composition as claimed by Claim 15 wherein the concentration of propylene glycol is from 12.0 mg/mL to 18.0 mg/mL.
17. The pharmaceutical composition as claimed by Claim 16 wherein the concentration of propylene glycol is from 14.0 mg/mL to 16.0 mg/mL.
18. The pharmaceutical composition as claimed by Claim 17 wherein the concentration of propylene glycol is 15.0 mg/mL.

19. The pharmaceutical composition as claimed by Claim 1 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from 5 mg/mL to 30 mg/mL; dibasic sodium phosphate concentration is from 0.67 mg/mL to 2.68 mg/mL; and propylene glycol concentration is from 14.0 mg/mL to 16.0 mg/mL.
20. The pharmaceutical composition as claimed by Claim 19 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from 5 mg/mL to 30 mg/mL; dibasic sodium phosphate concentration is 1.34 mg/mL; and propylene glycol concentration is 15.0 mg/mL.
21. The pharmaceutical composition as claimed by Claim 20 wherein the composition is presented in an automatic injection apparatus.
22. The pharmaceutical composition as claimed by Claim 13 wherein the pH of the composition is from 6.5 to 7.5.
23. The pharmaceutical composition as claimed by Claim 22 wherein the pH is from 6.7 to 7.3.
24. The pharmaceutical composition as claimed by Claim 23 further comprising one or more preservatives.
25. The pharmaceutical composition as claimed by Claim 24 wherein the composition further comprises a preservative selected from the group consisting of metacresol and phenol.
26. The pharmaceutical composition as claimed by Claim 25 wherein the preservative is metacresol.
27. The pharmaceutical composition as claimed by Claim 26 wherein the metacresol concentration is from 2.0 mg/mL to 4.0 mg/mL.
28. The pharmaceutical composition as claimed by Claim 27 wherein the metacresol concentration is 3.15 mg/mL.
29. The pharmaceutical composition as claimed by Claim 25 wherein the preservative is phenol.

30. The pharmaceutical composition as claimed by Claim 29 wherein the phenol concentration is from 3.0 mg/mL to 7.0 mg/mL.
31. The pharmaceutical composition as claimed by Claim 30 wherein the phenol concentration is 5.0 mg/mL.
32. The pharmaceutical composition as claimed by Claim 1 wherein tirzepatide, or

    pharmaceutically acceptable salt thereof, concentration is from 5 mg/mL to 30 mg/mL; dibasic sodium phosphate is from 0.67 to 2.68 mg/mL; propylene glycol is from 12.0 mg/mL to 15.0 mg/mL; and further comprising from 2.0 mg/mL to 4.0 mg/mL metacresol.
33. The pharmaceutical composition as claimed by Claim 1 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from 5 mg/mL to 30 mg/mL; dibasic sodium phosphate is from 0.67 to 2.68 mg/mL; propylene glycol is from 12.0 mg/mL to 18.0 mg/mL; and further comprising from 3.0 mg/mL to 7.0 mg/mL phenol.
34. The pharmaceutical composition as claimed by Claim 22 wherein the volume of the composition dose is 0.5 mL.
35. The pharmaceutical composition as claimed by Claim 34 wherein the composition is to be administered using an automatic injection apparatus.
36. Use of a pharmaceutical composition as claimed by Claim 22 in the manufacture of a medicament for treating diabetes.
37. The use of Claim 36, wherein the composition is to be administered using an automatic injection apparatus.
38. The use of Claim 37, wherein the composition is to be administered once weekly.
39. Use of a pharmaceutical composition as claimed by Claim 22 in the manufacture of a medicament for treating obesity.
40. The use of Claim 39, wherein the composition is to be administered using an automatic injection apparatus.

41. The use of Claim 40, wherein the composition is to be administered once weekly.
42. A pharmaceutical composition as claimed by Claim 22 for use in the treatment of diabetes.
43. A pharmaceutical composition as claimed by Claim 22 for use in the treatment of obesity.